Bridgebio Pharma And National Resilience Collaborate To Manufacture, Advance BBP-812, An Investigational Adeno-associated Virus (AAV) 9 Gene Therapy For Canavan Disease, And BBP-631, An Investigational AAV 5 Gene Therapy For Congenital Adrenal Hyperplasia
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma and National Resilience have partnered to manufacture and advance BBP-812, a gene therapy for Canavan disease, and BBP-631, a gene therapy for congenital adrenal hyperplasia. The collaboration aims to accelerate the development of these therapies.
October 03, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio Pharma's collaboration with National Resilience to manufacture and advance BBP-812 and BBP-631 could potentially accelerate the development and approval of these gene therapies, potentially boosting BridgeBio's stock in the short term.
The collaboration between BridgeBio Pharma and National Resilience could potentially accelerate the development and approval of BBP-812 and BBP-631. This could lead to increased revenues for BridgeBio in the future, which could positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100